Article

Pfizer, MediVas team for ophthalmic drug delivery

New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.

New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.

The deal centers on MediVas' fully biodegradable and biocompatible polymers in combination with Pfizer's ophthalmic compounds to increase therapy adherence and improve eye treatments.

MediVas is based in San Diego. Financial terms were not disclosed.

Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
© 2024 MJH Life Sciences

All rights reserved.